Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.47 |
| ▸ | FOS | P01100 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14778481 | 0.87 | ALOX15 (0.44) | CYP3A4MMP1ALOX15ALOX12FOS | |
| SCHEMBL14778479 | 0.87 | ALOX15 (0.44) | CYP3A4MMP1ALOX15ALOX12FOS | |
| SCHEMBL11911905 | 0.78 | CYP3A4 (0.75) | CYP3A4MMP1ALOX15ALOX12FOS | |
| SCHEMBL4072201 | 0.78 | CYP3A4 (0.75) | CYP3A4MMP1ALOX15ALOX12FOS | |
| SCHEMBL218706 | 0.78 | ALOX15 (0.43) | CYP3A4ALOX15ALOX12FOSTTR | |
| SCHEMBL3757544 | 0.76 | REN (0.55) | CYP3A4MMP1REN | |
| SCHEMBL7334535 | 0.76 | REN (0.55) | CYP3A4MMP1REN | |
| SCHEMBL220327 | 0.76 | REN (0.55) | CYP3A4MMP1REN | |
| SCHEMBL19316026 | 0.76 | MMP1 (0.49) | CYP3A4MMP1ALOX15ALOX12FOS | |
| SCHEMBL14221975 | 0.72 | CYP3A4 (0.61) | CYP3A4MMP1ALOX15ALOX12FOS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252288-A1 | ENANTIOSELECTIVE REDUCTION | DSM IP ASSETS B.V. (NL) | 2013-09-26 | — | — | US | disclosed |
| US-8088954-B2 | Preparation of a saturated aldehyde | DSM IP ASSETS B.V. (NL) | 2012-01-03 | — | — | US | disclosed |
| US-8088955-B2 | Alpha-substituted α,β-unsaturated E- or Z-aldehydes, use thereof, and processes for their preparation α,β | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG (AT) | 2012-01-03 | — | — | US | disclosed |
| US-20110301365-A1 | ALPHA-SUBSTITUTED ALPHA, BETA-UNSATURATED E- OR Z-ALDEHYDES, USE THEREOF, AND PROCESSES FOR THEIR PREPARATION ALPHA, BETA | DSM IP ASSETS B.V. (NL) | 2011-12-08 | — | — | US | disclosed |
| US-20110294171-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP ASSETS B.V. (NL) | 2011-12-01 | — | — | US | disclosed |
| US-20100234630-A1 | ALPHA-SUBSTITUTED A,B-UNSATURATED E- OR Z-ALDEHYDES, USE THEREOF, AND PROCESSES FOR THEIR PREPARATION A,B | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2010-09-16 | — | — | US | disclosed |
| CN-101801904-A | Alpha-substituted alpha, beta-unsaturated E-or Z-aldehydes, their use and processes for their preparation | DSM FINE CHEM AUSTRIA GMBH | 2010-08-11 | — | — | CN | disclosed |
| CN-101801903-A | Preparation of a saturated aldehyde | DSM IP ASSETS BV | 2010-08-11 | — | — | CN | disclosed |
| CN-101802207-A | The enantiomerism selective reduction | DSM IP ASSETS BV | 2010-08-11 | — | — | CN | disclosed |
| US-20100197972-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP ASSETS B.V. (NL) | 2010-08-05 | — | — | US | disclosed |
| EP-2178816-A1 | ALPHA-SUBSTITUTED , -UNSATURATED E- OR Z-ALDEHYDES, USE THEREOF, AND PROCESSES FOR THEIR PREPARATION , | DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) | 2010-04-28 | — | — | EP | disclosed |
| EP-2173696-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP Assets B.V. (NL) | 2010-04-14 | — | — | EP | disclosed |
| EP-2171077-A2 | ENANTIOSELECTIVE REDUCTION | DSM IP Assets B.V. (NL) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009007460-A2 | ENANTIOSELECTIVE REDUCTION | DSM IP ASSETS B.V. (NL) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007462-A1 | ALPHA-SUBSTITUTED α,β-UNSATURATED E- OR Z-ALDEHYDES, USE THEREOF, AND PROCESSES FOR THEIR PREPARATION α,β | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO. KG (AT) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007461-A1 | PREPARATION OF A SATURATED ALDEHYDE | DSM IP ASSETS B.V. (NL) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197972-A1 | PREPARATION OF A SATURATED ALDEHYDE | H1-0, F9, HRH4 | CYP3A4 120/4885MMP1 3849/4885ALOX15 516/4885 |
| US-20110301365-A1 | ALPHA-SUBSTITUTED ALPHA, BETA-UNSATURATED E- OR Z-ALDEHYDES, USE THEREOF, AND PROCESSES FOR THEIR PREPARATION ALPHA, BETA | CYP8B1, ECH1, NR1H2 | CYP3A4 146/4885MMP1 4114/4885ALOX15 71/4885 |
| US-20110294171-A1 | PREPARATION OF A SATURATED ALDEHYDE | H1-0, F9, HRH4 | CYP3A4 120/4885MMP1 3849/4885ALOX15 516/4885 |
| US-20100234630-A1 | ALPHA-SUBSTITUTED A,B-UNSATURATED E- OR Z-ALDEHYDES, USE THEREOF, AND PROCESSES FOR THEIR PREPARATION A,B | CYP8B1, CYP1B1, ADRA1A | CYP3A4 86/4885MMP1 4162/4885ALOX15 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.